Michael P Kriegler from La Jolla, CA

Assay Method For The Detection Of 26Kd Tnf Prohormone
view source
US Patent:

56862598, Nov 11, 1997
Filed:

Jun 5, 1995
Appl. No.:

8/463894
Inventors:

Michael Kriegler - San Francisco CA
Carl Perez - Berkeley CA
Assignee:

Chiron Corporation - Emeryville CA
International Classification:

G01N 3353
G01N 3358
C07K 1624
C07K 1626
US Classification:

435 792
Abstract:

Cleavage site blocking antibody that binds to prohormones, preferable Tumor Necrosis Factor, thereby preventing the formation of prohormone fragment(s) by proteolysis of the prohormone, and uses of the antibody including prophylactic and therapeutic methods to treat disease, and diagnostic assays for determining the amount of the prohormone and prohormone fragments present in a patients body.

Gene Fusion Encoding A Hypersecretor Protein
view source
US Patent:

58637974, Jan 26, 1999
Filed:

May 24, 1995
Appl. No.:

8/448897
Inventors:

Michael Kriegler - San Francisco CA
Carl F. Perez - Berkeley CA
Assignee:

Chiron Corporation - Emeryville CA
International Classification:

C12N 510
US Classification:

435366
Abstract:

A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.

Human Y-Interferon Signal Peptide-Tumor Necrosis Factor(Tnf) Gene Fusions
view source
US Patent:

53246551, Jun 28, 1994
Filed:

Feb 18, 1992
Appl. No.:

7/839017
Inventors:

Michael Kriegler - San Francisco CA
Carl Perez - Berkeley CA
Assignee:

Cetus Oncology Corporation - Emeryville CA
International Classification:

C12N 510
C12N 1511
C12N 1528
C12N 1563
US Classification:

4352402
Abstract:

A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF. Particularly disclosed is a DNA construct in which a gene encoding tumor necrosis factor (TNF) is directly linked to DNA encoding a human. gamma. -interferon signal peptide.

Compositions For The Inhibition Of Tnf Hormone Formation And Uses Thereof
view source
US Patent:

59983787, Dec 7, 1999
Filed:

Apr 19, 1994
Appl. No.:

8/230428
Inventors:

Michael Kriegler - Rancho Santa Fe CA
Carl Perez - San Diego CA
Robert F. Halenbeck - San Rafael CA
David A. Jewell - Sausalito CA
Kirston E. Koths - El Cerrito CA
Assignee:

Chiron Corporation - Emeryville CA
International Classification:

A61K 3800
US Classification:

514 18
Abstract:

Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the circulating level of mature protein hormones derived from the proteolytic cleavage of prohormone precursors such as 26 kDProTNF, and methods for identifying compounds having the desired inhibitory activity are provided.

Recombinant Host Cells Encoding Tnf Proteins
view source
US Patent:

58888144, Mar 30, 1999
Filed:

May 24, 1995
Appl. No.:

8/449073
Inventors:

Michael Kriegler - San Francisco CA
Carl F. Perez - Berkeley CA
Assignee:

Chiron Corporation - Emeryville CA
International Classification:

C12N 1574
C12N 508
US Classification:

435360
Abstract:

A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.

Method For Determining Tnf
view source
US Patent:

56395930, Jun 17, 1997
Filed:

May 17, 1996
Appl. No.:

8/649197
Inventors:

Michael Kriegler - San Francisco CA
Danute E. Nitecki - Berkeley CA
Assignee:

Cetus Oncology Corporation - Emeryville CA
International Classification:

C12Q 137
C07K 702
C07K 1481
US Classification:

435 4
Abstract:

Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, AIDS and autoimmune diseases.

Cleavage Site Blocking Antibody To Prohormone Proteins And Uses Thereof
view source
US Patent:

56771827, Oct 14, 1997
Filed:

Apr 18, 1995
Appl. No.:

8/424243
Inventors:

Michael Kriegler - San Francisco CA
Carl Perez - Berkeley CA
Assignee:

Chiron Corporation - Emeryville CA
International Classification:

C12N 512
C12N 522
C07K 1600
C07K 1624
US Classification:

435335
Abstract:

Cleavage site blocking antibody that binds to prohormones, preferable Tumor Necrosis Factor, thereby preventing the formation of prohormone fragment(s) by proteolysis of the prohormone, and uses of the antibody including prophylactic and therapeutic methods to treat disease, and diagnostic assays for determining the amount of the prohormone and prohormone fragments present in a patients body.

Method For Detecting The Presence Of P-Selectin
view source
US Patent:

60336676, Mar 7, 2000
Filed:

Nov 5, 1997
Appl. No.:

8/964690
Inventors:

Robert W. Chesnut - Cardiff CA
Margaret J. Polley - La Jolla CA
James C. Paulson - Del Mar CA
S. Tarran Jones - Radlett, GB
Jose W. Saldanha - Middlesex, GB
Mary M. Bendig - London, GB
Michael Kriegler - Rancho Santa Fe CA
Carl Perez - San Diego CA
Robert Bayer - San Diego CA
Michael Nunn - San Diego CA
Assignee:

Cytel Corporation - San Diego CA
International Classification:

A61K 39395
C07K 1628
C12N 512
C07H 2104
US Classification:

4241531
Abstract:

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.